Gå direkt till huvudinnehållet

Uroteliala cancertumörer i övre urinvägarna

Senast reviderad:
Sakkunnig:
Definition:
Cancer i övergångsepitelet som klär urinvägarna från njurbäcken till den yttre delen av uretra.
Förekomst:
Relativt sällsynt tillstånd med omkring 300 fall årligen i Sverige.
Symtom:
Typiska symtom är hematuri och flanksmärtor.
Kliniska fynd:
Inga kliniska fynd i tidiga stadier, vid avancerad sjukdom är utfyllnad i flanken ett möjligt fynd.
Diagnostik:
DT-urografi är förstahandsundersökningen vid klinisk misstanke om sjukdomen
Behandling:
Om patienten är operabel är huvudbehandlingen radikal kirurgi. Eventuellt adjuvant behandling i form av cytostatika eller strålning.
  1. Rouprêt M, Zigeuner R, Palou J, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update.. Eur Urol 2011; 59: 584-94. PubMed  
  2. Urinblåse- och urinvägscancer. Årsrapport nationellt kvalitetsregister 2016. www.cancercentrum.se  
  3. Cancer i urinblåsa, njurbäcken, urinledare och urinrör. Nationellt vårdprogram Regionala cancercentrum i samverkan. 2019. www.cancercentrum.se  
  4. Guruli G, Konety BR. Transitional cell carcinoma, renal. eMedicine, July 27, 2006.
  5. Kirkali Z, Tuzel E. Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol 2003; 47: 155-69. PubMed  
  6. Michaelson MD, Kaufman DS, Oh WK. Transitional cell carcinoma of the upper uroepithelial tract. Clin Adv Hematol Oncol 2003; 1: 102-4. PubMed  
  7. Berz D, Rizack T, Weitzen S, et al. Survival of patients with squamous cell malignancies of the upper urinary tract. Clin Med Insights Oncol 2012; 6: 11-8. PubMed  
  8. Cheville JC, Wu K, Sebo TJ, et al. Inverted urothelial papilloma: is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma?. Cancer 2000; 88: 632-6. PubMed  
  9. Rouprêt M, Drouin SJ, Cancel-Tassin G, et al. Genetic variability in 8q24 confers susceptibility to urothelial carcinoma of the upper urinary tract and is linked with patterns of disease aggressiveness at diagnosis. J Urol 2012; 187: 424-8. PubMed  
  10. Boorjian S, Ng C, Munver R, et al. Impact of delay to nephroureterectomy for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma. Urology 2005; 66: 283-7. PubMed  
  11. Audenet F, Traxer O, Yates DR, et al. Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract. BJU Int 2012; 109: 608-13. PubMed  
  12. Smith AK, Stephenson AJ, Lane BR, et al. Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology 2011; 78: 82-6. PubMed  
  13. Vassilakopoulou M, de la Motte Rouge T, Colin P, et al. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer 2011; 117: 5500-8. doi:10.1002/cncr.26172 DOI  
  14. Dasanu CA, Ong-Bacay A, Codreanu I. Newer developments in the therapeutics of the transitional cell carcinoma of renal pelvis. J Oncol Pharm Pract 2012; 18: 97-103. PubMed  
  15. Rai BP, Shelley M, Coles B, et al. Surgical management for upper urinary tract transitional cell carcinoma. Cochrane Database Syst Rev 2011:CD007349. Cochrane (DOI)  
  16. Stewart GD, Humphries KJ, Cutress ML, et al. Long-term comparative outcomes of open versus laparoscopic nephroureterectomy for upper urinary tract urothelial-cell carcinoma after a median follow-up of 13 years. J Endourol 2011; 25: 1329-35. PubMed  
  17. Eandi JA, Nelson RA, Wilson TG, Josephson DY. Oncologic outcomes for complete robot-assisted laparoscopic management of upper-tract transitional cell carcinoma. J Endourol 2010; 24: 969-75. PubMed  
  18. Cutress ML, Stewart GD, Wells-Cole S, et al. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int 2012. doi:10.1111/j.1464-410X.2012.11169.x DOI  
  19. Cutress ML, Stewart GD, Zakikhani P, et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int 2012. doi:10.1111/j.1464-410X.2012.11068.x DOI  
  20. Adamis S, Varkarakis J. Minimally invasive approach in the management of upper- urinary-tract tumours. Scand J Urol Nephrol 2011; 45: 381-7. PubMed  
  21. Bagley DH, Grasso M 3rd. Ureteroscopic laser treatment of upper urinary tract neoplasms. World J Uro 2010; 28: 143-9. PubMed  
  22. Irwin BH, Berger AK, Brandina R, et al. Complex percutaneous resections for upper-tract urothelial carcinoma. J Endourol 2010; 24: 367-70. PubMed  
  23. Silberstein JL, Power NE, Savage C, et al. Renal function and oncologic outcomes of parenchymal sparing ureteral resection versus radical nephroureterectomy for upper tract urothelial carcinoma. J Urol 2012; 187: 429-34. PubMed  
  24. Sobin DH, Wittekind CH, eds. In: TNM classification of malignant tumors. 6th. ed. New York: Wiley-Liss, 2002, p 199.
  25. Colin P, Ouzzane A, Pignot G, et al. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU Int 2012. doi:10.1111/j.1464-410X.2012.10960.x DOI  
  26. Lughezzani G, Burger M, Margulis V, et al. Prognostic Factors in Upper Urinary Tract Urothelial Carcinomas: A Comprehensive Review of the Current Literature. Eur Urol 2012 Epub ahead of print.
  27. Mouracade P, Velten M, Gigante M, et al. Factors impacting survival in patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy. Can J Urol 2012; 19: 6105-10. PubMed  
  28. Walsh, Retik, Vaughan, Wein (ed). Sagalowsky AI, Jarrett TW: Managements of urothelial tumors of the renal pelvis and ureter. In: Campell´s urology, eight edition. Philadelphia, London, New York St. Louis, Sydney, Toronto: Saunders, 2002.
  29. Favaretto RL, Shariat SF, Chade DC, et al. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 2010; 58: 574-80. PubMed  
  30. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33. PubMed  
  • Anna Nager, med dr och specialist i allmänmedicin, Karolinska institutet

Tidigare sakkunniga

  • Hans Hedelin, professor och överläkare, FoU-centrum och urologkliniken, Kärnsjukhuset, Skövde
  • Steinar J. Karlsen, tidligere klinikksjef og professor dr. med., Oslo Urologiske Universitetsklinikk, Aker universitetssykehus helseforetak og Universitetet i Oslo